![]() |
市场调查报告书
商品编码
1636726
吹灌封技术市场预测至 2030 年:按产品类型、机器类型、材料、自动化程度、应用和地区进行全球分析Blow Fill Seal Technology Market Forecasts to 2030 - Global Analysis By Product Type (Bottles, Ampoules, Vials, Pouches and Other Product Types), Machine Type (Carrousel, Linear and Rotary), Material, Level of Automation, Application and By Geography |
根据 Stratistics MRC 的数据,全球吹灌封技术市场预计在 2024 年将达到 34 亿美元,到 2030 年将达到 53 亿美元,预测期内的复合年增长率为 7.4%。
吹灌封 (BFS) 技术是一种先进的无菌製造技术,可在一个自动化过程中完成容器的製造、填充和密封。在製药和医疗领域,该技术经常用于包装无菌液体,包括眼药水和注射药物。透过最大限度地减少人为干预,降低污染的可能性,实现准确、可靠和经济的生产,吹灌封技术确保了产品的完整性。
根据IMS医疗资讯学研究所的一项研究,患者和医疗专业人员的不当使用药物每年给美国医疗保健系统造成超过2000亿美元的损失。
无菌包装需求不断成长
对无菌包装的需求不断增长是吹灌封 (BFS) 技术市场的主要驱动力。 BFS 技术可确保无污染包装,这对于药品、生技药品和疫苗至关重要。它将吹塑、填充和密封结合成一个自动化过程,从而提高了效率和产品安全性。医疗保健标准的不断提高和药品包装的严格监管要求进一步推动了其应用。此外,它在食品和饮料行业的卫生包装应用扩大了市场潜力,使其成为各行业不可或缺的一部分。
小批量弹性有限
机械和设置成本高昂,使其适合大规模生产,而不适用于小型或小众产品线。这项限制影响了小型製药公司和专业产品製造商的采用。随着客製化需求的增加,BFS 系统缺乏扩充性成为一个挑战,迫使製造商创新解决方案以满足小批量和大量生产的需求。
专注于永续包装
随着环境问题日益严重,业界正在转向更环保的材料,例如用于 BFS 应用的可回收聚乙烯 (PE) 和聚丙烯 (PP)。此外,轻量化包装解决方案的进步减少了材料的使用和碳足迹。透过与全球永续性目标保持一致,BFS 技术供应商可以扩大其市场范围,同时为寻求更环保替代品的产业提供服务,而不会影响无菌性或效率。
医疗监管法规的变化
医疗保健法规的频繁变化对BFS技术市场构成了威胁。药品包装合规标准的区域差异给全球营运的製造商带来了复杂的问题。对使用的材料和无菌检验过程的监管审查会增加营运成本并延迟产品核可。违规的风险包括经济处罚和声誉损害。
COVID-19 疫情对 BFS 技术市场产生了双重影响。一方面,对疫苗和注射药物无菌包装的需求激增,凸显了无污染解决方案的重要性。另一方面,供应链中断导致机械生产和原材料供应延迟。儘管有这些挑战,疫情凸显了BFS技术在医疗保健领域的重要作用,确保了长期成长前景。
预计预测期内聚乙烯(PE)市场规模将占最大比重。
由于聚乙烯 (PE) 在 BFS 应用中广泛使用,预计在预测期内将占据最大的市场占有率。 PE 耐用、灵活,且与药品相容。它的可回收性符合永续性,进一步鼓励人们采用。 PE 容器广泛用于眼药水和注射剂等液体药品,因为它们具有成本效益并且能保持无菌。这一领域的主导地位反映了其在各行各业的多功能性。
预计预测期内製药业将实现最高的复合年增长率。
由于对无菌药物输送系统的需求不断增加,预计预测期内製药业将出现最高的复合年增长率。 BFS 技术可确保液体药物、生技药品和疫苗的无污染包装,同时符合严格的监管标准。慢性病的增加和生技药品製造的进步推动了该领域对无菌包装解决方案的需求。这一领域的快速成长证明了其在现代医疗保健体系中的重要角色。
由于北美拥有先进的医疗保健基础设施且高度重视药品包装的技术创新,预计在预测期内北美将占据最大的市场占有率。强调无菌的监管要求导緻美国和加拿大的製药公司广泛采用 BFS 技术。此外,在研发方面的大量投资推动了技术进步,使包装过程更加高效、更加安全,巩固了北美的主导地位。
由于经济快速发展、医疗保健基础设施扩张以及中国和印度等国家药品产量不断增加,预计亚太地区将在预测期内实现最高成长率。该地区对经济实惠的医疗保健解决方案的关注正在推动对 BFS 等具有成本效益的无菌包装技术的需求。人们对产品安全和品质意识的不断提高进一步推动了市场的成长,亚太地区是全球扩张的主要贡献者。
According to Stratistics MRC, the Global Blow Fill Seal Technology Market is accounted for $3.4 billion in 2024 and is expected to reach $5.3 billion by 2030 growing at a CAGR of 7.4% during the forecast period. Blow fill seal (BFS) technology is a sophisticated aseptic manufacturing technique that allows containers to be made, filled, and sealed all at once using an automated process. In the pharmaceutical and medical fields, this technology is frequently used to package sterile liquids, including eye drops and injectable medications. By minimizing human involvement, lowering the possibility of contamination, and providing accurate, dependable, and economical production, blow fill seal technology guarantees product integrity.
According to a study by the IMS Institute for Healthcare Informatics, the improper use of medications by patients and healthcare providers costs the U.S. healthcare system more than $200 billion annually.
Growing demand for sterile and aseptic packaging
The increasing demand for sterile and aseptic packaging is a primary driver for the blow-fill-seal (BFS) technology market. BFS technology ensures contamination-free packaging, crucial for pharmaceuticals, biologics, and vaccines. Its ability to combine blowing, filling, and sealing into one automated process enhances efficiency and product safety. Rising healthcare standards and stringent regulatory requirements for drug packaging further boost adoption. Additionally, its application in food and beverage industries for hygienic packaging expands its market potential, making it indispensable across multiple sectors.
Limited flexibility for small batch sizes
The high cost of machinery and setup is better suited for large-scale manufacturing, making it less viable for small or niche product lines. This limitation affects its adoption among smaller pharmaceutical companies or specialty product manufacturers. As customization demands increase, the lack of scalability in BFS systems poses challenges, requiring manufacturers to innovate solutions that cater to both small and large-scale production needs.
Focus on sustainable packaging
With rising environmental concerns, industries are shifting toward eco-friendly materials like recyclable polyethylene (PE) and polypropylene (PP) in BFS applications. Additionally, advancements in lightweight packaging solutions reduce material usage and carbon footprints. By aligning with global sustainability goals, BFS technology providers can expand their market reach while catering to industries seeking greener alternatives without compromising on sterility or efficiency.
Changes in healthcare regulations
Frequent changes in healthcare regulations pose a threat to the BFS technology market. Variations in regional compliance standards for pharmaceutical packaging create complexities for manufacturers operating globally. Regulatory scrutiny over materials used and sterility validation processes increases operational costs and delays product approvals. Non-compliance risks include financial penalties and reputational damage.
The COVID-19 pandemic had a dual impact on the BFS technology market. On one hand, demand surged for aseptic packaging of vaccines and injectable medications, highlighting the importance of contamination-free solutions. On the other hand, supply chain disruptions delayed machinery production and raw material availability. Despite these challenges, the pandemic underscored the critical role of BFS technology in healthcare, ensuring long-term growth prospects.
The polyethylene (PE) segment is expected to be the largest during the forecast period
The polyethylene (PE) segment is expected to account for the largest market share during the forecast period due to its widespread use in BFS applications. PE offers excellent durability, flexibility, and compatibility with pharmaceutical products. Its recyclability aligns with sustainability initiatives, further boosting adoption. PE-based containers are widely used for liquid pharmaceuticals like eye drops and injectables due to their ability to maintain sterility while being cost-effective. The segment's dominance reflects its versatility across various industries.
The pharmaceuticals segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the pharmaceuticals segment is expected to witness the highest CAGR due to increasing demand for sterile drug delivery systems. BFS technology ensures contamination-free packaging of liquid drugs, biologics, and vaccines while meeting stringent regulatory standards. The rising prevalence of chronic diseases and advancements in biologics manufacturing drive the need for aseptic packaging solutions in this sector. The segment's rapid growth underscores its critical role in modern healthcare systems.
The North America region is anticipated to account for the largest market share during the forecast period due to its advanced healthcare infrastructure and strong focus on innovation in pharmaceutical packaging. Regulatory requirements emphasizing sterility drive widespread adoption of BFS technology across pharmaceutical companies in the U.S. and Canada. Additionally, significant investments in R&D foster technological advancements that enhance efficiency and safety in packaging processes, solidifying North America's leadership position.
The Asia Pacific region is anticipated to register the highest growth rate over the forecast period owing to rapid economic development, expanding healthcare infrastructure, and increasing pharmaceutical production in countries like China and India. The region's focus on affordable healthcare solutions drives demand for cost-effective aseptic packaging technologies like BFS. Rising awareness about product safety and quality further supports market growth, positioning Asia Pacific as a key contributor to global expansion.
Key players in the market
Some of the key players in Blow Fill Seal Technology Market include Rommelag Engineering, Unither Pharmaceuticals, Catalent, Recipharm, Weiler Engineering, The Ritedose Corporation, Nephron Pharmaceuticals, Takeda Pharmaceuticals, GlaxoSmithKline, LyondellBasell Industries, Gerresheimer, Unicep Packaging, Amanta Healthcare, Horizon Pharmaceuticals, SALVAT, Curida, Asept Pak and BioConnection.
In December 2024, Catalent, Inc. a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences investment firm, today announced that Novo Holdings has completed its previously announced acquisition of Catalent in an all-cash transaction with a total enterprise value of approximately $16.5 billion.
In October 2024, Recipharm, a leading global pharmaceutical contract development and manufacturing organisation (CDMO), is expanding its pharmaceutical development capabilities, through targeted investments and the integration of cutting-edge technologies. This investment bolsters its services for early- and late- stage product development, including clinical study supply at small and pilot scales and wide range of commercial technologies.
In October 2024, IsomAb Ltd, a UK-based biotechnology company developing isoform-specific disease modifying antibody treatments for serious and life-threatening diseases, today announced it has entered into a strategic collaboration with Catalent, Inc. the leader in enabling the development and supply of better treatments for patients worldwide. The Master Service Agreement (MSA) encompasses development of ISM-001 from cell line development through to finished clinical trial product supply; work will be performed in the USA and the EU. IsomAb will retain ongoing decision-making autonomy and full rights to the program throughout the collaboration.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.